Lexicon Pharmaceuticals, Inc., a prominent entity in the biopharmaceutical sector, has been actively engaged in the development of innovative treatments across a spectrum of health conditions. Based in The Woodlands, United States, Lexicon Pharmaceuticals operates within the health care sector, specifically focusing on biotechnology. The company is publicly traded on the Nasdaq stock exchange, with its shares priced at $1.4 as of December 4, 2025. This valuation reflects a significant fluctuation over the past year, with a 52-week high of $1.66 on October 9, 2025, and a low of $0.28 on March 2, 2025.
With a market capitalization of approximately $508.76 million, Lexicon Pharmaceuticals has demonstrated resilience in a competitive industry. Despite facing challenges, as indicated by a negative price-to-earnings ratio of -7.4, the company continues to pursue its mission of discovering and developing novel therapeutics. The company’s research endeavors span a diverse range of medical fields, including diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease.
Since its Initial Public Offering (IPO) on April 7, 2000, Lexicon Pharmaceuticals has maintained a commitment to advancing medical science and improving patient outcomes. The company’s strategic focus on addressing unmet medical needs positions it as a key player in the biotechnology landscape. By leveraging cutting-edge research and development, Lexicon Pharmaceuticals aims to bring transformative treatments to market, thereby enhancing the quality of life for patients worldwide.
For further information, stakeholders and interested parties are encouraged to visit Lexicon Pharmaceuticals’ official website at www.lexpharma.com . The company’s ongoing efforts to innovate and expand its therapeutic portfolio underscore its dedication to contributing to the broader health care ecosystem.
